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Abstract
Background:Oral bosentan has been widely applied in pulmonary arterial hypertension associated with congenital heart disease
(PAH-CHD). A systemic review and meta-analysis was conducted for a therapeutic evaluation of oral bosentan in both adult and
pediatric patients with PAH-CHD. The acute responses and a long-term effect were respectively assessed in a comparison with
baseline characteristics, and the improvement of exercise tolerance was analyzed.
Methods:PubMed, Medline, Embase, and Cochrane Central Register of clinical controlled trails or observational studies have been
searched for a recording of bosentan effects on the PAH-CHD participants. For mortality and rate of adverse events (AEs), it was
described in detail. Randomized-effects model or fixed-effects model was used to calculate different effective values with a sensitivity
analysis.
Results:Seventeen studies were pooled in this review, and 3 studies enrolled the pediatric patients. Among all studies, 456 patients
were diagnosed with PAH-CHD, and 91.7% were treated with oral bosentan. With a term less than 6 months of bosentan therapy,
there existed a significant improvement in 6-minute walk distance (6MWD) and theWorld Health Organization functional class (WHO-
FC), but no such differences in Borg dyspnea index scores (BDIs) and the resting oxygen saturation (SpO2). Although with a
prolonged treatment, not only 6MWD and FC, but also the resting SpO2 and heart rate were changed for a better exercise capability.
Additionally, compared with the basic cardiopulmonary hemodynamics, it showed a statistically significant difference in mean
pulmonary arterial pressure (mPAP) and pulmonary vascular resistance index (PVRi). Although a limitation of pooled studies with
comparative outcomes of different terms, outcomes presented a lower WHO-FC which contributes to a success in a prolonged
treatment.
Conclusions: Bosentan in PAH-CHD is well established and still requires clinical trials for an identification of its efficiency on CHD
patients for an optimized period lessening a serious complication and the common AEs.
Abbreviations: AE = adverse event, CHD = congenital heart disease, CI = confidence interval, ERA = endothelin receptor
antagonist, ES = Eisenmenger syndrome, ET = endothelin, FC = functional class, mPAP =mean pulmonary artery pressure, 6MWD
= 6-minute walk distance, PAH = pulmonary arterial hypertension, PCWP = pulmonary capillary wedge pressure, PVRi = pulmonary
vascular resistance index, RCT = randomized controlled trail, SMD = standardized mean differences.
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Pulmonary arterial hypertension (PAH) is a progressive disease
with negative prognosis leading to right heart failure and
premature death.[1] It is defined as a mean pulmonary artery
pressure (mPAP) ≥25mmHg in peace, also with a decreasing
pulmonary capillary wedge pressure (PCWP) and increased
pulmonary vascular resistance index (PVRi) via right heart
catheterization.[2]
PAH is a common complication of congenital heart disease
(CHD), especially with systemic-to-pulmonary shunts in children
owing to an increasing pulmonary blood flow.[3] In that
condition, it possibly causes obstructive lesions and persistently
increasing PVRi. A timely corrective surgery is a critical
prevention from a progressive pulmonary vascular changes
and PAH in childhood. However, with the advances of pediatric
interventions and cardiac surgery, a growth population with
complex CHD in adulthood that may develop progressive
vascular remodeling, causing an irreversible condition of
Eisenmenger syndrome (ES). The prevalence of PAH in ES
conditions probably is about 1% to 6%.[4,5] PAH associated with
CHD (PAH-CHD) could be classified into 4 groups in clinical:
group A, ES; group B, PAH associated with left to right shunts;
group C, PAH with small defects (VSD<1cm and ASD<2cm
assessed by echocardiogram); and group D, PAH after corrective
cardiac surgery.[4]
In the pathophysiological progress, an elevated plasma level
of endothelin (ET)-1, a vasoactive peptide that commonly
considered as an important role driving fibrosis, vascular
hypertrophy, proliferation, and vasoconstriction. Two identi-
fied receptor sub-type, including ET-A and ET-B, have influence
on vascular smooth muscle.[6] Endothelin receptor antagonists
(ERAs) mainly covers 4 medical agents in specific PAH
therapy. Bosentan is a dual ET-A/ET-B ERA which is widely
in clinical. In previous summary, it was identified as safe and
well tolerated in PAH adults and children with or without a
combination management.[7,8] A qualitative systematic review
about bosentan in adults with PAH-CHD has indicated a
significant improvement in exercise capacity (6-minute walk
distance [6MWD] and clinical functional class [FC]) and
hemodynamic parameters in 2014.[9] Although it was sup-
ported a short-term improvement of ERA in both adults and
children with left-to-right shunts while a decline effect at a long-
term follow-up. There still are with a lack of systemic analysis
about efficiency in both a short-term and a long duration for
patients with PAH-CHD. Consequently, we performed a meta-
analysis and systemic review of patients with PAH-CHD to
have a further idea of the structural and functional effects of
bosentan.Table 1
Search strategy.
Search terms
1. Endothelin receptor antagonist or bosentan
2. Pulmonary arterial hypertension or PAH
3. Congenital heart disease or CHD
4. 1, 2, and 3
CHD= congenital heart disease, PAH=pulmonary arterial hypertension.2. Methods
This systematic review and meta-analysis was conducted and
reported in adherence to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement (PRISMA)[10]
and the guidelines of the Cochrane Handbook for Systematic
Reviews of Interventions.[11] Since this study was a review
of previous published studies, ethical approval or patient
consent was not a requirement. The literature search, eligibility
evaluation and data extraction were carried out by 2 reviewers
(HY-K and YH-W) independently. And the language was not
limited to English. The ethical approval was waived for a review
and analysis of pooled studies published.22.1. Literature search and selection criteria
PubMed, Medline, the Cochrane Library, and EMBASE were
searched for records. The search strategy is shown in Table 1. The
last search was conducted on September 29, 2017. The cited
references of retrieved articles and previous reviews were
manually checked to identify any additional eligible trails. And
the investigators screened the study inclusion for twice. Studies
meeting the following criteria were considered as the eligible:
Population: patients were diagnosed with PAH-CHD and
monitored not mixed with other causes (including age of
<18 years or adults or both); Intervention: a monotherapy of
bosentan; Study design: randomized controlled trails (RCTs) or
clinical controlled trails or observational studies; Outcome:
primary outcomes were comprised of mortality, exercise capacity
(6MWD), World Health Organization (WHO) modification of
FC, heart rate (HR), Borg dyspnea index scores (BDIs), and the
resting oxygen saturation (SpO2); the secondary outcomes
mainly include cardiopulmonary hemodynamic parameters,
mostly like mPAP, PVRi, and PCWP, etc., the morbidity of
adverse events (AEs); and Study exclusion: the study without
important outcomes, an evaluation of medicine on PAH with
other cardiopulmonary lesions, and a combined therapy with
other specific medicines, such as prostanoids and phosphodies-
terase inhibitor and a study with a medical transition were all
removed. Discrepancies of included studies between 2 authors
(H-YK and Y-HW) were resolved by a discussion with the
correspondence author (T-WL).
2.2. Data extraction
All relevant data were independently documented by 2 of the
authors (H-YK and Y-HW) from each enrolled trail by using a
unified data form. The items of extracted data included study
characteristics (first author, publication year, and sample size of
participants), pharmacotherapy intervention (active drug), and
outcomes (primary outcomes and secondary outcomes). The oral
term was defined as a short-term when less than 6 months, and a
long period effect when more than it. Any discrepancies were
resolved by consensus. And we contacted the authors to obtain
original information through e-mail when necessary. For those
abstracts, we have reviewed and excluded for not meeting the
criteria. This study did not enroll the unpublished studies.
2.3. Quality assessment
RCTs were assessed using the Cochrane Risk-of-Bias tool.[12]
And we adopted the Newcastle-Ottawa Scale for assessing the
quality of Case–Control studies and Cohort studies (www.ohri.
ca/programs/clinical_epidemiology/oxford.asp).
2.4. Statistical analysis
To evaluate the effects of PAH-specific medicine in PAH-CHD,
we computed 95% confidence intervals (CIs) of standardized
Kuang et al. Medicine (2018) 97:10 www.md-journal.commean differences (SMD) for the continuous outcome data.
Heterogeneity across pooled studies was tested using Cochrane Q
via a Chi2 test, quantifying with the I2 statistic, P< .05 and I2>
50% indicates a significant heterogeneity between studies, and
then a sensitivity analysis was used to explore the sources of
heterogeneity.[13] After unavailability of homogenization, a
random effect model of analysis was employed. Otherwise, a
fixed effect model of analysis was applied to calculate pooled
SMD and 95% CIs. Begg test was carried out to investigate
publication bias of enrolled studies.[14] All the statistical analyses
were analyzed with Stata 14.1 software (StataCorp, TX), and a
P value was stated statistically significant when less than .05.3. Results
3.1. Study identification and selection
The selection process was portrayed in Fig. 1. A total of 853
records were identified by the search strategy. About 110 articles
were excluded for duplication. After reviewing the title and
abstract, 701 articles were excluded for guidelines, reviews, case
reports, animal trails, and ineligible participants (or pharmaco-
therapy). Finally, the remaining 42 full-text articles were assessed
for the eligibility. Five articles were removed for a combined
specific drug. Additional 11 articles were excluded for depicting
those patients not only with CHD (including 9 articles with other
etiology of PAH or 7 articles with CHD and 21-trisomy). The
remaining 4 articles were excluded for a lack of important
outcomes. Eventually, 17 trails[15–31] were enrolled in the meta-
analysis. And 418/456 participants were treated with oral
bosentan for a diagnosis of PAH secondary to CHD.
3.2. Study characteristics
The main characteristics of these included studies are demon-
strated in Table 2. The included studies were published between
2005 and 2016, which was comprised of 15 cohort studies
(10 prospective studies and 5 retrospective studies) 1 RCT and 1
clinical controlled trail. Among these 17 trails, 2 were conducted
in China, 2 in US, 2 in Netherlands, 2 in UK, 2 in Germany, 2 inFigure 1. Selection flowchart of literatu
3Italy, 1 in Greece, 1 in France, 1 in Portugal, 1 in India, and 1 in
Iran. Three trails just identified the safety and efficiency of
bosentan in pediatric patients with CHD.[25–27] In these 3 studies,
the dose of bosentan was afforded according to body weight. And
the patients involved in the remaining studies were treated with
bosentan in a dosage of 62.5mg twice daily in the first 4 weeks,
after which, increasing this to 125mg twice daily, as tolerated.
Nine studies have mentioned patients suffered from ES, and the
percentage of ES was about 49.6%. And about 34 patients were
diagnosed with postoperative associated with PAH. All basic
characteristics in enrolled articles are shown in Table 2.
Additionally, the baseline, short-term, and long-term character-
istics of all pooled studies were described in Table 3.3.3. Quality assessment
The quality of the studies is assessed respectively by the
Cochorane Risk-of-Bias Tool in Table 4 and Newcastle-Ottawa
Scale in Tables 5 and 6. Almost all articles were evaluated as a
high quality, except for 1 study of 5 stars.[26]
3.4. All efficiency of bosentan pharmacotherapy in
PAH-CHD
Patients had no treatment regimen changes. Data for the
efficiency of all PAH-specific management were extracted from
all enrolled studies. In bosentan treatment group, a total of 14
patients was reported with a death endpoint. Although AEs
occurred in 43 subjects mentioned in 13 articles, with a greater
proportion of edema (25.6%), liver dysfunction (18.6%),
headache (14.0%), palpitations (11.6%), chest pain (6.9%),
flushing (6.9%), and other AEs (11.6%), which included a throat
pain and hypoglycemia each episode. In pediatric management,
Gillbert has reported a case with an elevating liver enzymes to
about 3-fold the upper limit of normal.[27]3.5. Short-term outcomes
After receiving a short-term oral bosentan, patients presented
exercise capacity mainly in 6MWD (N=8, in a study includingre screening for the meta-analysis.
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Table 4
Risk-of-bias assessment of included randomized controlled trails
∗
.
Study
(first author)
Adequate
sequence
generation?
Allocation
concealment?
Blinding
of
participants
Blinding
of
assessment
Incomplete
outcomes
data addressed?
Selective
reporting?
Free of
other bias?
Overall
risk of bias
Galie et al Yes Yes Yes Yes Unclear No Yes High
∗
Risk of bias was assessed with use of the Cochrane risk-of-bias tool.
Table 5
Assessment the quality of case–control studies
∗
.
Selection Exposure
Score
Study
(first author)
Definition
adequate?
Representativeness
of cases
Selection
of controls
Definition
of controls Comparability†
Ascertainment
of exposure
Same method
of ascertainment
Nonresponse
rate
Riel – 8
∗
The assessment was based on the Newcastle-Ottawa Scale. The full mark of total score is defined as 9; a score of >7 indicates a low risk of bias.
† Comparability of cases and controls on the bias of design or analysis.
Kuang et al. Medicine (2018) 97:10 Medicinedifferent groups data with PAH-CHD). In this meta-analysis,
heterogeneity test revealed heterogeneity chi-squared=39.50,
P< .01, I2=82.3%, indicating a significant heterogeneity. The
sensitivity analysis was employed and it was uncovered a
significant after excluding the pooled study by Sitbon et al.[28] A
random effect model of analysis was used in Fig. S1 http://links.
lww.com/MD/C158, showing an increase level of 6MWD (I2=
53.3%, SMD=1.201; 95%CI=0.696–1.705; P< .01). As other
important indicators of exercise capacity, WHO-FC was
identified a significant change (I2=39.1%, SMD=1.332; 95%
CI=0.931–1.734; P< .01) and scores of BDIs in 3 studies were
assessed with an unsatisfactory improvement (I2=0%, SMD=
0.534; 95%CI=0.173–1.242; P= .139) The resting SpO2 was
not been elevated in a short-term with a significant statistical
difference (I2=44.7%, SMD=0.139; 95%CI=0.418–0.140;
P= .328). HR was not regularly recorded in a short-term
monitoring. The cardiopulmonary hemodynamics, coveringTable 6
Assessment the quality of cohort studies
∗
.
Selection
Study
(first author)
Representativeness
of exposed cohort
Selection of
nonexposed
cohort
Ascertainment of
exposure
to implants
Demons
that out
Ibrahim –
Apostolopoulou –
Schulze-Neick –
D’Alto –
Vis –
Baptisa –
Diller –
Ye –
Ajami
Xu – –
Gilbert –
Sitbon –
Benza –
Mehta –
Durongpisitkul –
∗
The assessment was based on the Newcastle-Ottawa Scale. The full mark of total score is defined a
† A demonstration about the outcomes of interest was not present initially.
‡ Comparability: study controls the most important factor in a monotherapy of bosentan; additional imp
x Subjects lost to follow-up: small number lost: <5%.
6mPAP, PVRi, and PCWP, were the secondary outcomes. The
data were mentioned in studies showing a great heterogeneity in
each hemodynamic parameters, including mPAP (4 studies): I2=
71.6%; PVRi (3 studies): I2=83.3%; and PCWP (2 studies): I2=
84.3%. After a discussion, meta-analysis could not be employed
in these parameters.3.6. Long-term outcomes
After a pharmacotherapy of oral bosentan more than 6 months,
the exercise capacity was evaluated. In 6MWDassessment during
a long-term, heterogeneity test revealed I2=59.7%, and a
sensitivity analysis was applied presenting an abnormal deviation
of study conducted by Apostolopoulou et al.[18] from others in
Fig. L1 http://links.lww.com/MD/C158. The deviated study was
excluded, and a fixed-effect model was applied in Fig. L2 http://
links.lww.com/MD/C158 (I2=21.5%, SMD=0.697; 95%CI=Outcome
tration
come† Comparability‡ Assessment
Enough
follow-up
Adequacy
of follow
up of cohortsx Score
– 7
8
8
8
8
– 7
8
– 7
– 7
– 5
– 7
8
8
8
– 7
s 9; a score of >7 indicates a low risk of bias
ortant factor is a collection of data in a cohort group with PAH-CHD.
Figure 2. The publication bias of long-term efficiency of bosentan treatment
with Begg funnel plot.
Kuang et al. Medicine (2018) 97:10 www.md-journal.com0.552–0.872; P< .001). TheWHO-FC assessment in a long-term
follow-up. After excluded the study researched by D’Alto et al[20]
and Mehta et al,[30] it was calculated a heterogeneity chi-
squared=9.85, P= .131, I2=39.1%. A fixed-effects model was
employed (SMD=1.394, 95%CI=1.652 to 1.137; P
< .001), revealing a statistically significant difference in a
decrease of FC evaluation which suggested a great improvement
in exercise tolerance. The resting SpO2 and HR were also as the
symbols of exercise capacity, which was evaluated a lasting
efficiency respectively in 8 studies[17,19–23,29,31–32] and 4
studies[19–22] of statistical significance. (SpO2: I
2=15.9%, SMD
=0.268, 95%CI=0.065–0.472, P= .01; HR: I2=44.2%, SMD
=0.323, 95%CI=0.599 to0.047, P= .022). The BDIs were
monitored comparing with baseline data in 5 pooled studies,
indicating an unobvious decline to baseline condi-
tion,[17,18,21,23,29] (I2=45.1%, SMD=0.257, 95%CI=
.528–0.014, P= .063). For a further hemodynamic changes
rather than an acute response, bosentan could significantly lower
the parameter in mPAP (I2=0%, SMD=0.236, 95%CI=
.458 to 0.014, P= .037), in PVRi (I2=0%, SMD=0.423,
95%CI=0.663 to 0.184, P= .001), but with little change in
PCWP (I2=14.4%, SMD=0.038, 95%CI=0.184–0.259,
P= .739).
3.7. Comparative outcomes
A comparative analysis was conducted between short-term and
long-term treatment for a quantitative review. Between a short-
term and a long-term period, 6MWD was compared in 6 pooled
trails with a great heterogeneity (I2=89.1%).[17,18,23,24,29,32]
After a sensitivity analysis, the study by Apostolopoulou et al[18]
was excluded, and it indicated an increase 6MWD not
significantly compared with short-term outcomes (I2=0%,
SMD=0.140, 95% CI=0.210–0.490, P= .434). Although it
was identified with a significant decrease in WHO-FC (I2=0%,
SMD=0.401, 95%CI=0.677 to 0.125, P= .004). The
resting SpO2 in a long-term period was showed a higher level
than that in a short-term period without statistical difference
(I2=0%, SMD=0.079, 95%CI=0.264–0.422, P= .651).
Meanwhile, after a prolonged treatment of oral bosentan in
3 studies, the scores of BDIs were decreased, but the difference
was not significant (P= .822).73.8. Pediatric PAH-CHD therapy
In the 3 studies just enrolled the pediatric patients, including 1 in
Iran,[25] 1 in China,[26] and 1 in Germany.[27] Totally, the subjects
counted 45. Three individuals were recorded the death endpoint
and 1 AE scenario was detected in a study, presenting an
increasing liver enzymes.[27] Two studies depicted mPAP
presenting a lower pressure in a short-term treatment.[25,26] In
study conducted by Xu et al.,[26] there was existed an
improvement in exercise capacity, identifying by 6MWD
increasing by 17.2% (from 424±31m increased to 497±56
m). FC was also expressed as a lowering level compared with the
initial time point not only in a pilot with a short-term therapy
from 3.44 (0.68) to 2.17 (0.37), but also in another study with a
long-term treatment from 2.6 (0.6) to 1.6 (0.6).
3.9. Publication bias
For the meta-analysis in a long-term efficiency of bosentan
treatment acting on 6MWD, there is existed no evidence of
significant publication bias by the inspection of the Begg funnel
plot in Fig. 2.
4. Discussion
In PAH patients associated with CHD could suffer from an
increasing mortality and morbidity of severe conditions.[3,32] In
postoperative PAH patients, it commonly formed an abnormal
vascular resistance before surgery, after which, an acute response
caused by vascular lesions and cardiopulmonary bypass.
Although a sharply increasing blood flow in the systemic
circulation could lead to acute left heart failure, presenting as a
fatal scenario as pulmonary hypertensive crisis. PAH with left-to
right shunts progressively causes the pulmonary vascular
changes, to some extent, leading to the irreversible remodeling.
Furthermore, the pulmonary vascular resistance persistently
increased, and once the pulmonary vascular resistance exceeded
the systemic circulation resistance, ES occurs which was totally
freedom from a treatment of surgical management. For PAH
patients with CHD, ERAs have been proved efficient in both
monotherapy and combination therapy. Bosentan, a nonselec-
tive, dual ET-A/ET-B ERA, has been approved by FDA in 2001,
and Current European Society of Cardiology guidelines have
been recommended that bosentan therapy is initiated in PAH-
CHD patients, even ES patients.[33]
In our study, we proved that a dual ERA, bosentan is a safe and
efficient medicine for PAH-CHD patients in both adults and
children, not only for ES, but also for PAH patients with closured
systemic-to-pulmonary shunts. Previously, Kara et al proved
benefits in mPAP and right heart function in ES patients during a
lasting treatment.[34] Although, a qualitative systematic review
has suggested an important functional benefit of bosentan
therapy, while a limited evaluation in hemodynamics.[10] The
drawbacks and AEs were considerable, especially a hepatotoxic-
ity with elevated transaminase level most frequently in previous
studies.[35] Currently, 17 trails were pooled in this review. Most
studies enrolled adult subjects. The mean mortality was about
4.5% in 13 studies and AEs were counted as 13.7%. But AEs
were showed just a greater proportion in peripheral edema than
higher liver enzymes and other complications. These events were
commonly reported a relief after a pause or decreasing dosage
of bosentan. A mortality of all pooled studies indicated no
significance. The traditional medicines (eg, oral anticoagulation,
calcium channel blockers, and diuretics), but other ERAs, PDE-5
Kuang et al. Medicine (2018) 97:10 Medicineinhibitors, and prostacyclin analogues, were combined with
bosentan in patients preoperative or postoperative both in adult
and pediatric PAH-CHD patients.
Van Loon et al[36] found that bosentan therapy was shown to
produce only short-term improvement in WHO-FC and 6MWD
in both children and adults with PAH-CHD. Guo et al[37] have
reviewed 8 trails and discussed bosentan was an efficient and
tolerated treatment for CHD-PAH patients. However, it was just
showed an increasing exercise capacity in a period of 3 to 6
months but a significant difference with a long-term, also leaving
out the vascular parameters, safety, and AEs. A 2-year
observational study also reported an improvement in 6MWD
with ERA monotherapy proving a lasting effect on patients.[34]
But there was still a lack of comparative analysis.
We conducted this meta-analysis constructing from a short-
term period (<6m) and a long-term period (≥6m). And the
idiopathic PAH (iPAH) and PAH associated with connective
tissue diseases were all freedom from this review. On the other
hand, those PAH-CHD subjects with Down syndrome were not
enrolled. Data were on important surveillance indicators of
exercise tolerance in a short-term therapy which indicated a
significant difference in 6MWD andWHO-FC, but there were no
obvious changes in the resting SpO2. A considerable heterogene-
ity of cardiopulmonary hemodynamics detected by right
catheterization was among each pooled studies. Hence, the
changes in vascular hemodynamic parameters remained limited
statistical significance. With a period of long-term, the evidence
supported that ERA could further be safe and well tolerated
compared with baseline. Outcomes demonstrated a clinical
functional benefit of bosentan therapy, such as 6MWD, WHO-
FC, and HR. Additionally, bosentan also improved the
hypoxemia condition with or without ES patients. However,
the scores of BDIs were still not decreased neither in a short-term
therapy nor in a long-term therapy. In hemodynamic parameters,
mPAP and PVRi were lowered a lot by bosentan treatment when
a long-term therapy in patients with PAH-CHD. Hence, it is
considered a possible importance of a prolonged therapy, which
was contrary to some previous studies.[19,36]
Although clinically functional benefits were found either a
short-term or a long-term outcomes compared with baseline
characteristics. The necessity of a prolonged therapy with a dual
ERA still is to be certified for a prevention from the AEs. For those
studies with a prolonged treatment of monotherapy, the
comparative outcomes were suggested a meaningful decline in
WHO-FC. To the contrary, the results indicated a prolonged
therapy of oral bosentan possibly could not an increase walking
distance of 6MWD and the resting SpO2, and a decrease the
scores of BDIs significantly, which possibly was ascribed to a
limitation of small sample capacity. Hence, we held a point of
view that a prolonged treatment in PAH-CHD possibly a
necessity, not only improving the clinical manifestations but also
declining vascular resistance, and controlling the remodeling in
pulmonary vessels as proved previously.[38]
It seemly exists a smaller proportion of ES group in pediatric
patients, and the studies also supported an empirical clinical
value of ERAs in children. But it lacked a qualitative proof for
it. It is commonly known that a limited treatment strategy in
adult PAH-CHD, especially ES conditions. Some PAH patients
occurred after CHD occlusion.[4,39] In addition, the participants
with trisomy-21 were excluded in this study, and the efficiency of
ERAs contributing to in these individuals were neglected. For the
greater numbers of patients with PAH-CHD surviving into
adulthood inoperably, especially with complex CHD, specific-8PAH therapy can improve the functional status and exercise
tolerance which was recommended by ESC guidelines.[40] Our
study has some limitations which are as follows: The effects were
evaluated together, without the subgroup analysis in different
CHD group; A small sample of trials with controlled group; and
Risk of death and AEs could not calculated and compared
between ERA treatment group and a blank group. Else, the
optimal identification of clinical manifestations and cardiopul-
monary hemodynamic parameters between the short period
effect and long period effect remains to be explored in future
trails.5. Conclusions
Current evidence indicates that bosentan is a safe and effective
specific-PAH therapy for PAH-CHD patients. Although this
review was conducted without a differentiated analysis in CHD
classification. We can conclude that this dual ERA is an effective
treatment both in a short-term and a long-term, which suggesting
an irreplaceable strategy in PAH with systemic-to-pulmonary
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